NASDAQ:ICLR - ICON Public Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $236.00
  • Forecasted Upside: 11.15 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$212.32
▼ -0.39 (-0.18%)

This chart shows the closing price for ICLR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ICON Public Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICLR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICLR

Analyst Price Target is $236.00
▲ +11.15% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for ICON Public in the last 3 months. The average price target is $236.00, with a high forecast of $280.00 and a low forecast of $200.00. The average price target represents a 11.15% upside from the last price of $212.32.

This chart shows the closing price for ICLR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in ICON Public. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/30/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/29/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/27/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/24/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2021MizuhoBoost Price TargetBuy$217.00 ➝ $242.00Low
4/29/2021Credit Suisse GroupBoost Price TargetOutperform$240.00 ➝ $245.00Low
4/29/2021Jefferies Financial GroupBoost Price TargetBuy$256.00 ➝ $267.00Low
4/13/2021Bank of AmericaInitiated CoverageNeutralMedium
4/1/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$200.00 ➝ $235.00Medium
3/8/2021BarclaysInitiated CoverageEqual Weight$200.00N/A
3/8/2021Robert W. BairdUpgradeNeutral ➝ Outperform$215.00Low
3/2/2021BarclaysInitiated CoverageEqual Weight$200.00High
3/1/2021UBS GroupUpgradeNeutral ➝ Buy$207.00 ➝ $232.00Low
2/26/2021TruistUpgradeHold ➝ Buy$280.00High
2/25/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$179.00 ➝ $208.00Medium
10/23/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$170.00 ➝ $179.00Medium
10/23/2020MizuhoBoost Price TargetBuy$195.00 ➝ $217.00Medium
10/22/2020Credit Suisse GroupBoost Price TargetOutperform$230.00 ➝ $235.00Medium
7/27/2020UBS GroupBoost Price TargetNeutral$188.00 ➝ $194.00Low
7/27/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$135.00 ➝ $170.00Low
7/27/2020MizuhoBoost Price TargetBuy$170.00 ➝ $195.00Low
7/24/2020Bank of AmericaDowngradeBuy ➝ NeutralLow
7/24/2020Jefferies Financial GroupBoost Price TargetBuy$184.00 ➝ $220.00Low
7/23/2020Credit Suisse GroupBoost Price TargetOutperform$181.00 ➝ $205.00High
4/27/2020SunTrust BanksBoost Price TargetHold$131.00 ➝ $157.00Medium
4/24/2020Deutsche Bank AktiengesellschaftLower Price TargetHold$169.00 ➝ $135.00Medium
4/23/2020Credit Suisse GroupLower Price TargetOutperform$187.00 ➝ $181.00High
4/23/2020BarclaysBoost Price TargetOverweight$170.00 ➝ $180.00High
4/20/2020Robert W. BairdDowngradeOutperform ➝ Neutral$151.00Low
4/9/2020CitigroupLower Price TargetNeutral$185.00 ➝ $160.00Medium
4/3/2020MizuhoLower Price TargetBuy$180.00 ➝ $154.00Low
3/30/2020Wells Fargo & CompanyLower Price TargetEqual Weight$180.00 ➝ $140.00Low
3/26/2020BarclaysUpgradeEqual Weight ➝ Overweight$182.00 ➝ $170.00High
3/23/2020Jefferies Financial GroupLower Price TargetBuy$180.00 ➝ $146.00High
3/17/2020SunTrust BanksLower Price TargetHold$182.00 ➝ $131.00Medium
3/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$169.00High
2/21/2020UBS GroupBoost Price TargetNeutral$174.00 ➝ $182.00Medium
2/20/2020BarclaysBoost Price TargetEqual Weight$168.00 ➝ $182.00High
2/20/2020MizuhoReiterated RatingBuy$179.00 ➝ $194.00High
1/27/2020SunTrust BanksDowngradeBuy ➝ Hold$170.00 ➝ $182.00Medium
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$180.00Low
1/6/2020CitigroupInitiated CoverageNeutral$185.00Low
10/28/2019Credit Suisse GroupReiterated RatingBuy$160.00Low
10/25/2019UBS GroupSet Price TargetHold$160.00N/A
10/18/2019UBS GroupLower Price TargetNeutral$171.00 ➝ $158.00Low
8/8/2019KeyCorpBoost Price TargetOverweight$157.00 ➝ $165.00Medium
7/26/2019UBS GroupUpgradeSell ➝ Neutral$135.00 ➝ $171.00Low
7/25/2019MizuhoBoost Price TargetBuy$160.00 ➝ $170.00High
6/11/2019MizuhoBoost Price TargetBuy$154.00 ➝ $160.00Low
4/17/2019BarclaysReiterated RatingHold$154.00High
4/2/2019Wolfe ResearchInitiated CoverageOutperformLow
3/18/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$140.00 ➝ $148.00Low
2/25/2019SunTrust BanksReiterated RatingBuy$161.00Medium
2/21/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$130.00 ➝ $140.00Low
1/25/2019MizuhoUpgradeNeutral ➝ Buy$146.00 ➝ $150.00Medium
12/14/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$168.00Medium
10/27/2018UBS GroupSet Price TargetSell$136.00Medium
10/26/2018Evercore ISIUpgradeIn-Line ➝ OutperformMedium
10/9/2018UBS GroupInitiated CoverageSell ➝ Sell$145.00Medium
9/11/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$154.00 ➝ $157.00Low
9/11/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$152.00 ➝ $157.00Low
8/6/2018MizuhoSet Price TargetHold$146.00Medium
7/26/2018Robert W. BairdReiterated RatingBuy$154.00High
7/26/2018SunTrust BanksBoost Price TargetBuy$153.00High
6/19/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$131.00 ➝ $144.00Medium
6/18/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$130.00 ➝ $152.00Low
6/1/2018Jefferies Financial GroupBoost Price TargetBuy$150.00Medium
2/16/2018Credit Suisse GroupUpgradeBuy$131.00Low
2/15/2018MizuhoReiterated RatingNeutral ➝ Neutral$109.00 ➝ $114.00Low
1/24/2018MizuhoSet Price TargetHold$109.00Low
1/22/2018SunTrust BanksReiterated RatingBuy$133.00Low
1/18/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$126.00High
1/11/2018KeyCorpReiterated RatingBuy$130.00Medium
11/13/2017KeyCorpReiterated RatingOverweight$115.00 ➝ $125.00N/A
10/29/2017SunTrust BanksReiterated RatingReduce ➝ Buy$138.00N/A
10/27/2017BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$108.00 ➝ $120.00N/A
10/16/2017Credit Suisse GroupReiterated RatingOutperform$105.00 ➝ $120.00N/A
10/12/2017Robert W. BairdReiterated RatingBuy$123.00N/A
10/9/2017Jefferies Financial GroupBoost Price TargetBuy$122.00 ➝ $132.00N/A
9/12/2017Jefferies Financial GroupReiterated RatingBuy$122.00Low
9/11/2017Bank of AmericaInitiated CoverageBuy ➝ Buy$128.00Low
7/31/2017KeyCorpReiterated RatingOverweightMedium
7/31/2017SunTrust BanksUpgradeHold ➝ Buy$93.00 ➝ $126.00Medium
7/30/2017Jefferies Financial GroupReiterated RatingBuyMedium
7/28/2017Credit Suisse GroupReiterated RatingBuyLow
7/27/2017MizuhoBoost Price TargetNeutral ➝ Neutral$104.00 ➝ $108.00Low
7/7/2017The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$117.00High
6/29/2017Jefferies Financial GroupUpgradeHold ➝ Buy$86.00 ➝ $117.00Medium
6/9/2017Robert W. BairdLower Price TargetOutperform$107.00 ➝ $97.00Low
6/6/2017Credit Suisse GroupReiterated RatingOutperform$91.00 ➝ $102.00Low
5/11/2017Jefferies Financial GroupReiterated RatingHoldLow
4/28/2017Evercore ISIBoost Price TargetOutperform$91.50 ➝ $92.00Low
3/23/2017MizuhoInitiated CoverageNeutral$66.00Low
1/24/2017Jefferies Financial GroupBoost Price TargetHold$84.00 ➝ $86.00N/A
1/6/2017Jefferies Financial GroupReiterated RatingHold$87.50 ➝ $84.00N/A
12/16/2016The Goldman Sachs GroupUpgradeNeutral ➝ Buy$86.00 ➝ $90.00N/A
12/16/2016SunTrust BanksDowngradeBuy ➝ Hold$95.00 ➝ $80.00N/A
10/24/2016Jefferies Financial GroupReiterated RatingHold$80.00 ➝ $87.50N/A
10/20/2016Avondale PartnersUpgradeUnderperform ➝ Market PerformN/A
10/14/2016Evercore ISIUpgradeHold ➝ Buy$81.50 ➝ $89.00N/A
7/27/2016KeyCorpReiterated RatingBuy$85.00N/A
7/27/2016Jefferies Financial GroupBoost Price TargetHold$78.00 ➝ $80.00N/A
7/26/2016Evercore ISIBoost Price TargetHold$76.00 ➝ $81.50N/A
6/27/2016Robert W. BairdReiterated RatingOutperform$83.00N/A
(Data available from 6/22/2016 forward)
ICON Public logo
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $212.32
Low: $209.65
High: $213.56

50 Day Range

MA: $218.58
Low: $196.43
High: $232.20

52 Week Range

Now: $212.32
Low: $158.63
High: $234.22

Volume

878,724 shs

Average Volume

573,214 shs

Market Capitalization

$11.39 billion

P/E Ratio

33.49

Dividend Yield

N/A

Beta

0.85

Frequently Asked Questions

What sell-side analysts currently cover shares of ICON Public?

The following Wall Street research analysts have issued reports on ICON Public in the last year: Bank of America Co., Barclays PLC, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Mizuho, Robert W. Baird, Truist, UBS Group AG, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for ICLR.

What is the current price target for ICON Public?

9 Wall Street analysts have set twelve-month price targets for ICON Public in the last year. Their average twelve-month price target is $236.00, suggesting a possible upside of 11.2%. Truist has the highest price target set, predicting ICLR will reach $280.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $200.00 for ICON Public in the next year.
View the latest price targets for ICLR.

What is the current consensus analyst rating for ICON Public?

ICON Public currently has 3 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ICLR will outperform the market and that investors should add to their positions of ICON Public.
View the latest ratings for ICLR.

What other companies compete with ICON Public?

How do I contact ICON Public's investor relations team?

ICON Public's physical mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company's listed phone number is (531) 291-2000. The official website for ICON Public is www.iconplc.com.